Exceptional Response in BRAF p.V600E-Mutant Enteric-Type Adenocarcinoma of the Lung With Cutaneous Spread: A Case Report

• Published in: JTO clinical and research reports 2023, Vol.4 (12), p.100597-100597
• Main Authors: Sposito, Marco, Scaglione, Ilaria Mariangela, Eccher, Serena, Pasqualin, Luca, Avancini, Alice, Colato, Chiara, Rosina, Paolo, Simbolo, Michele, Caliò, Anna, Scarpa, Aldo, Milella, Michele, Pilotto, Sara, Belluomini, Lorenzo
• Format: Report
• Language: English
• ISSN: 2666-3643
• DOI: 10.1016/j.jtocrr.2023.100597

BackgroundEnteric-type adenocarcinoma of the lung (lung-ETAC) is a rare form of lung cancer with histologic similarities to colorectal cancer, with aggressive behavior and unfavorable prognosis.Case PresentationAn 81-year-old man presented with discolored skin lesions on the chest and abdomen. After comprehensive evaluation, including skin biopsy and molecular profiling, the patient was diagnosed with having lung-ETAC with a BRAF p.V600E mutation. Treatment with dabrafenib and trametinib initially resulted in positive results, with improvement in skin lesions and overall clinical condition. Nevertheless, approximately 6 months after, the disease had progression with new skin lesions reappearing.ConclusionsWe reported a unique case of a patient with BRAF p.V600E-mutant lung-ETAC with metastatic skin lesions achieving complete cutaneous response after targeted treatment with dabrafenib and trametinib, highlighting the potential for targeted therapy in patients with lung-ETAC harboring a BRAF p.V600E mutation.